Myriad Genetics Chief Commercial Officer Separates
Myriad Genetics Inc. has separated from its Chief Commercial Officer, Brian Donnelly, effective September 21, 2026. The departure is part of a separation agreement resulting in a lump sum payment of $1,322,294.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed